Original Article

You have full text access to this OnlineOpen article

Protein expression and gene amplification of epidermal growth factor receptor in thymomas

  1. Diana N. Ionescu M.D.1,†,*,
  2. Elizaburo Sasatomi M.D., Ph.D.1,
  3. Kathleen Cieply B.S.1,
  4. Marin Nola M.D., Ph.D.2,
  5. Sanja Dacic M.D., Ph.D.1

Article first published online: 3 JAN 2005

DOI: 10.1002/cncr.20811

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 630–636, 1 February 2005

Additional Information

How to Cite

Ionescu, D. N., Sasatomi, E., Cieply, K., Nola, M. and Dacic, S. (2005), Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer, 103: 630–636. doi: 10.1002/cncr.20811

Author Information

  1. 1

    Division of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Presbyterian University Hospital, Pittsburgh, Pennsylvania

  2. 2

    Department of Pathology, School of Medicine University of Zagreb, Zagreb, Croatia

  1. †

    Fax: (412) 647-7799

*Division of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Presbyterian University Hospital, 200 Lothrop St. PUH A610.2, Pittsburgh, PA 15213

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 3 JAN 2005
  3. Manuscript Accepted: 14 OCT 2004
  4. Manuscript Revised: 4 OCT 2004
  5. Manuscript Received: 5 JUL 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (205K)

REFERENCES

  • 1
    Bernatz PE, Harrison EG, Glagett OT. Thymoma. A clincopathologic study. J Thorac Cardiovasc Surg. 1961; 42: 424–444.
  • 2
    Kirchner T, Muller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Pathol. 1989; 10: 167–190.
  • 3
    Marino M, Muller-Hermelink HK. Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch A. 1985; 407: 119–149.
  • 4
    Moran CA, Suster S. Current status of the histologic classification of thymoma. Int J Surg Pathol. 1995; 31: 67–72.
  • 5
    Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of neoplasms of thymic epithelium. Am J Clin Pathol. 1999; 111: 826–833.
  • 6
    Quintanilla-Martinez L, Wilkins EW Jr., Ferry JA, Harris NL. Thymoma-morphologic subclassification correlates with invasiveness and immunohistologic features: a study of 122 cases. Hum Pathol. 1993; 24: 958–969.
  • 7
    Pescarmona E, Rendina EA, Venuta F, Ricci C, Ruco LP, Baroni CD. The prognostic implication of thymoma histologic subtyping. A study of 80 consecutive cases. Am J Clin Pathol. 1990; 93: 190–195.
  • 8
    Ho FC, Fu KH, Lam SY, Chiu SW, Chan AC, Muller-Hermelink HK. Evaluation of a histogenetic classification for thymic epithelial tumours. Histopathology. 1994; 25: 21–29.
    Direct Link:
  • 9
    Kuo TT, Lo SK. Thymoma: a study of the pathologic classification of 71 cases with evaluation of the Muller-Hermelink system. Hum Pathol. 1993; 24: 766–771.
  • 10
    Pan CC, Wu HP, Yang CF, Chen WY, Chiang H. The clinicopathological correlation of epithelial subtyping in thymoma: a study of 112 consecutive cases. Hum Pathol. 1994; 25: 893–899.
  • 11
    Quintanilla-Martinez L, Wilkins EW Jr., Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer. 1994; 74: 606–617.
    Direct Link:
  • 12
    Rosai J. The World Health Organization histological typing of tumours of the thymus. 2nd ed. Berlin: Springer Verlag, 1999: 9–13.
  • 13
    Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma. A clinical study of 273 patients. Cancer. 2002; 94: 624–632.
    Direct Link:
  • 14
    Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer. 2003; 105: 494–498.
    Direct Link:
  • 15
    Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors. A clinicopathologic study of 200 thymoma cases from China. Cancer. 2002; 95: 420–429.
    Direct Link:
  • 16
    Sasaki H, Ide N, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer. 2002; 101: 342–347.
    Direct Link:
  • 17
    Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994; 44: 359–367.
    Direct Link:
  • 18
    Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48: 2485–2492.
    Direct Link:
  • 19
    Schmidt-Wolf IGH, Rockstroh JK, Schuller H, et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol. 2003; 82: 69–76.
  • 20
    Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg. 1999; 4: 562–572.
  • 21
    Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer. 2002; 94: 1405–1413.
    Direct Link:
  • 22
    Evoli A, Lo Monaco M, Marra R, Lino MM, Batocchi AP, Tonali PA. Multiple paraneoplastic diseases associated with thymoma. Neuromuscul Disord. 1999; 9: 601–603.
  • 23
    Marx A, Schultz A, Wilisch A, Helmreich M, Nenninger R, Muller-Hermelink HK. Paraneoplastic autoimmunity in thymus tumors. Dev Immunol. 1998; 6: 129–140.
  • 24
    Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991; 51: 152–156.
  • 25
    Salyer WR, Eggleston JC. Thymoma: a clinical and pathological study of 65 cases. Cancer. 1976; 37: 229–249.
    Direct Link:
  • 26
    Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg. 1995; 60: 908–914.
  • 27
    Nicholson RI, Gee JMW, Harper ME. EGRF and cancer prognosis. Eur J Cancer. 2001; 37: S9–S15.
  • 28
    Hayashi Y, Ishii N, Obayashi C, et al. Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch A. 1995; 426: 43–50.
  • 29
    Gilhus NE, Jones M, Turley H, et al. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol. 1995; 48: 447–455.
  • 30
    Pescarmona E, Pisacane A, Pignatelli E, Baroni CD. Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology. 1993; 23: 39–44.
    Direct Link:
  • 31
    Henley JD, Koukoulis GK, Loehrer PJ. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol. 2002; 128: 167–170.
  • 32
    Sasaki H, Yukiue H, Sekimura A, et al. Elevated serum epidermal growth factor receptor level in stage IV thymoma. Surg Today. 2004; 34: 477–479.
  • 33
    Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48: 2485–2492.
    Direct Link:
  • 34
    Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest. 2004; 84: 582–587.
  • 35
    Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck. 1992; 14: 8–13.
    Direct Link:
  • 36
    Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 2003; 25: 67–73.
    Direct Link:
  • 37
    Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001; 7: 1850–1855.
  • 38
    Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993; 71: 2454–2460.
    Direct Link:
  • 39
    O'dwyer PJ, Benson AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 2002; 29: 10–17.
  • 40
    Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13: 3–17.
  • 41
    Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J. 2002; 20: 975–981.
  • 42
    Kopp R, Ruge M, Rothbauer E, et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 2002; 22: 1161–1167.
  • 43
    Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol. 2002; 87: 84–89.
  • 44
    Saltz LB, Mvropol NJ, Loelirer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of Cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201–1207.
  • 45
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer. Targeting epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–2970.
  • 46
    Buerger H, Packeisen J, Boecker A, et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequnce—first results of an inter-ethnic breast cancer study. J Pathol 2004; 203: 545–550.
    Direct Link:
  • 47
    Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000; 157: 257–266.
  • 48
    Zhou R, Zettl A, Strobel P, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol. 2001; 159: 1853–1860.
  • 49
    Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651–3664.
  • 50
    Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001; 19: 2714–2721.
  • 51
    Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13: 63–72.
View Full Article (HTML) Get PDF (205K)